News

Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.

In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.

An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.

National deaths from heart disease spiked in 2020 in the beginning of the COVID-19 pandemic, after an observed steady decline from 2010 to 2019.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

New phase 2 data show a synthetic, proprietary 25 mg dose from COMPASS may fare better for adult patients than a 10 mg dose.

Only 12% of people with CVD older than age 65 used wearable devices, despite estimates suggesting half of all people with CVD are older than age 65.

The 30-year analysis suggests a significantly higher risk associated with lead exposure and lower risk for particulate matter in the US than in the UK.

There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.

With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

In a late-breaking abstract, investigators assess how pantoprazole 40 mg daily effects long-term kidney function.

In a late-breaking abstract, investigators assess how discontinuation of ACEi or ARBs impact disease progression for advanced CKD.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.

Approximately 1 out of every 6 patients with COVID-19 had a reduced eGFR.

Females generally have a lower risk of cardiovascular disease compared to males.

Data presented during ASN 2022 shows how heart failure impacts risk factors for renal outcomes of patients with chronic kidney disease.

An analysis of over-the-counter products show not all AMD-targeting supplements match the recommended dosage from the National Institutes of Health.

In this study, the investigators assessed risk factors in patients with DRESS syndrome receiving vancomycin to treat gram-positive infections.

An analysis of serum dupilumab treatment for atopic dermatitis patients suggests a lack of association between either response or adverse effects.

The FDA recently approved a drug treatment for HBV infection for pediatric patients 12 and older with compensated liver disease.

A recent study into autoimmune and metabolic disturbances identified an association between these conditions and vitiligo cases.

Patients with obesity have higher costs and longer hospital stays for IBD.

New data from the International Pediatric Sleep Association (IPSA) Congress 2022 used smart bed technology that revealed consistent findings to previous studies.

Only 7% of trials included a patient-reported outcome measure as a primary outcome measure.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.